Aytu BioPharma (NASDAQ:AYTU) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Aytu BioPharma (NASDAQ:AYTU) to a hold rating in a research report report published on Saturday morning.

A number of other research firms have also weighed in on AYTU. Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Friday, January 9th. Zacks Research downgraded Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research note on Friday, January 30th. Finally, Ascendiant Capital Markets lifted their price target on Aytu BioPharma from $12.50 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Three analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Aytu BioPharma presently has a consensus rating of “Hold” and a consensus price target of $9.33.

Aytu BioPharma Stock Performance

Shares of NASDAQ AYTU opened at $2.29 on Friday. The business’s 50-day simple moving average is $2.53 and its 200-day simple moving average is $2.34. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.03 and a current ratio of 1.16. Aytu BioPharma has a 52 week low of $0.95 and a 52 week high of $3.07. The firm has a market cap of $24.57 million, a price-to-earnings ratio of -0.60 and a beta of 0.37.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.79). Aytu BioPharma had a negative net margin of 39.02% and a negative return on equity of 28.22%. The company had revenue of $15.17 million for the quarter, compared to analyst estimates of $12.17 million.

Institutional Investors Weigh In On Aytu BioPharma

Institutional investors and hedge funds have recently bought and sold shares of the business. AWM Investment Company Inc. acquired a new position in Aytu BioPharma in the second quarter worth about $1,351,000. FNY Investment Advisers LLC acquired a new stake in Aytu BioPharma in the 2nd quarter valued at $78,000. Stonepine Capital Management LLC boosted its stake in Aytu BioPharma by 75.3% in the 2nd quarter. Stonepine Capital Management LLC now owns 812,676 shares of the company’s stock valued at $1,772,000 after buying an additional 348,955 shares in the last quarter. Bellevue Asset Management LLC acquired a new stake in shares of Aytu BioPharma in the 4th quarter valued at $65,000. Finally, Two Sigma Investments LP grew its holdings in shares of Aytu BioPharma by 96.2% in the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after purchasing an additional 33,701 shares during the last quarter. Institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.